Company Interview / FDA greenlight for Neuren’s trial

Jon Pilcher of Neuren Pharmaceuticals says the FDA's approval of the primary endpoints for the phase three trial of their drug for Phelan-McDermid syndrome is pivotal. Jon expresses relief over a smooth and productive interaction with the FDA, which allows them to proceed further.

Jon outlines the significance of their drug, aiming to enhance neural connectivity for this neurological disorder. He hopes it brings groundbreaking impact on communication, cognitive ability, and overall quality of life for those affected. The trial will compare outcomes over three months, with plans to expand treatment duration afterwards.

With robust funding from prior success in Rett syndrome treatments, Neuren feels well-positioned to finance this trial. Despite recent share price volatility, Jon remains optimistic about future investor reception, emphasizing their solid financial foundation and promising value opportunities ahead.